Todays News

Alpha Peak is a new brain health metric that provides personalized cognitive performance scoring and brain health support. TORONTO--(BUSINESS WIRE)--Muse® by Interaxon, a leader in brain health and neurotechnology, proudly announces the launch of a new cognitive performance metric, Alpha Peak. As the first in a suite of advanced brain health metrics, Alpha Peak empowers users to enhance cognitive performance through personalized, actionable insights with an easy-to-understand score—paving the way for enhanced mental fitness. As we age, cognitive decline becomes an increasingly significant concern with no convenient way to measure it. Research indicates that certain cognitive functions, including memory, executive functions, processing speed, and reasoning, begin to decline from as early as the 30s1. Furthermore, studies suggest that mild cognitive impairment (MCI) affects 10-20% of adults over 65, with the potential to evolve into more severe cognitive issues if left unmanaged2. Introducing Alpha Peak: The HRV of the Brain Similar to how heart rate variability (HRV) provides insights into cardiovascular health, Alpha Peak can help you understand your brain’s aging process and take charge of your cognitive health. Research indicates that alpha peak frequency (APF) varies with age: it increases during childhood, peaking in early adulthood, and declining thereafter. This pattern suggests APF is closely tied to cognitive maturation and aging. A 2016 foundational study involving over 6,000 participants using Muse devices found a strong correlation between APF and cognitive performance, including overall cognitive health, processing speed, and memory3. By leveraging Muse mEEG devices to measure individual APF after biofeedback sessions, users can obtain a cognitive performance score with personalized tips for optimizing alpha wave activity. After completing a few Muse sessions, a personalized baseline is established, and users will receive a graph showing whether their Alpha Peak falls within, below, or above this baseline. As users monitor lifestyle factors such as diet, exercise, and sleep, they can directly correlate these changes with their Alpha Peak score and receive personalized prompts to optimize their habits accordingly. “Muse has strategically positioned itself at the forefront of brain health by focusing on key areas such as enhancing focused attention, revolutionizing at-home sleep support, and now with Alpha Peak, advancing cognitive performance,” said Jean-Michel Fournier, CEO of Muse. “Each of these initiatives aligns with our audacious goal of improving brain health globally, through accessible advanced neurotechnology.” Advancing Brain Health with Innovative Research Muse’s commitment to brain health goes beyond cognitive performance, driving research across multiple critical areas such as sleep and cognitive decline: AI-Powered Sleep Diagnostics & Therapeutics: Muse’s mEEG headbands, equipped with advanced sleep staging algorithms, offer unmatched precision and scalability compared to traditional diagnostic methods. Advanced sleep analysis is now more accessible to researchers and clinicians worldwide, pushing the boundaries beyond traditional sleep staging with macro and micro architecture insights. Formative research with esteemed partners in the fields of depression, insomnia, and PTSD explores novel sleep interventions with Muse devices and the intricate relationships between sleep and these conditions, working towards creating strategies that could significantly enhance the quality of life for those affected. Brain Age & Cognitive Decline: Last year, Muse published research with over 5,000 participants on the effects of aging on brain function, leading to the development of a “Brain Age Score”4. A breakthrough metric that would allow users to track the health and age of their brain relative to their chronological age, providing actionable insights for maintaining and improving cognitive health over time. In 2024, a large-scale study focused on mild cognitive decline (MCI) will be conducted in partnership with principal investigator Dr. Olav Krigolson from the University of Victoria, aiming to improve MCI diagnosis and tracking using Muse devices for at-home brain measurements. “The ability to measure brain health in real-time with Muse’s technology is a game-changer for diagnosing and managing mild cognitive impairment,” said Dr. Olav Krigolson PhD, professor and principal investigator of the study. “This research has the potential to revolutionize early intervention strategies, offering new hope for those at risk of cognitive decline.” About Muse by Interaxon Inc Muse is pioneering brain health through its industry-leading mEEG platform, built on advanced AI algorithms. Muse spearheads decentralized research initiatives focused on enhancing mental health, optimizing sleep, and advancing cognitive performance through innovative neurotechnology. Muse’s AI-driven neurotech tools empower researchers, developers, and consumers worldwide, and is underpinned by over 200 third-party-led research studies from renowned institutions including the Mayo Clinic, MIT, and Harvard. Muse has collected and decoded over 1 billion minutes of brain data to-date, comprising one of the largest EEG collections in the world. Muse is headquartered in Toronto, Canada. Visit choosemuse.com/pages/cognitive-performance for more information and connect with us on Instagram, Facebook, TikTok, Twitter, and LinkedIn. For access to the Muse’s recent white paper, Enhancing Sleep Diagnostics with AI-Powered EEG Technology visit musehealth.ai/pages/sleep-resources 1 Ian J. Deary, Janie Corley, Alan J. Gow, Sarah E. Harris, Lorna M. Houlihan, Riccardo E. Marioni, Lars Penke, Snorri B. Rafnsson, John M. Starr, Age-associated cognitive decline, British Medical Bulletin, Volume 92, Issue 1, December 2009, Pages 135–152, https://doi.org/10.1093/bmb/ldp0332 Alzheimers.gov. (n.d.). What is Mild Cognitive Impairment? Retrieved from https://www.alzheimers.gov3 Hashemi A, Pino LJ, Moffat G, Mathewson KJ, Aimone C, Bennett PJ, Schmidt LA, Sekuler AB. Characterizing Population EEG Dynamics throughout Adulthood. eNeuro. 2016 Dec 12;3(6):ENEURO.0275-16.2016. doi: 10.1523/ENEURO.0275-16.2016. PMID: 27957533; PMCID: PMC5150228. 4 Hubert Banville, Maurice Abou Jaoude, Sean U.N. Wood, Chris Aimone, Sebastian C. Holst, Alexandre Gramfort, Denis-Alexander Engemann; Do try this at home: Age prediction from sleep and meditation with large-scale low-cost mobile EEG. Imaging Neuroscience 2024; 2 1–15. doi: https://doi.org/10.1162/imag_a_00189 Contacts Julia Park Marketing Coordinator julia@interaxon.cachoosemuse.com

CEO Stephane Degove will provide corporate overviews at Sachs’ 20th Annual Biotech in Europe Forum in Basel, Chardan’s 8th Annual Genetic Medicines Conference in New York City, and the Cell & Gene Meeting on the Mesa in Phoenix. The company also will make 6 presentations on its limb-girdle muscular dystrophy (LGMD) clinical development and research programs at 3 scientific conferences in the US and Europe. A publication in Nature Communications describes the work of CSO Isabelle Richard team on the use of artificial intelligence (AI) to design a new generation of capsids for more effective gene therapy vectors. EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation in six upcoming conferences in the US and Europe to highlight recent developments in its programs targeting limb-girdle muscular dystrophies (LGMDs). Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan's 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024. • Sach’s 20th Annual Biotech in Europe Forum, held in Basel, Switzerland, on September 25-26, 2024:   Presentation on September 25, at 11:40 am (CEST), in the Ruby Room. • Chardan's 8th Annual Genetic Medicines Conference, held in New York City, on September 30 and October 1, 2024:   Presentation on September 30 at 11:00 am (US EDT), in the Embassy Room. • Cell & Gene Meeting on the Mesa, held in Phoenix, AZ, on October 7-9, 2024:   Presentation on October 8, at 5:45 pm (US MST), at the FLW Ballroom F. Two communications at the 29th Annual Congress of the World Muscle Society, October 8-12, 2024, in the Prague Congress Centre, Prague, Czech Republic, will describe Atamyo’s LGMD programs. • “Preliminary results from a Phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with Limb Girdle Muscular Dystrophy R9.”   Oral presentation by S. Olivier (Atamyo), at Congress Hall on Saturday, October 12, 2024, 8 am - 8:15 am (CEST) • “MRI characterization of the cardiac involvement in LGMD2i/R9.”   JY Hogrel (Institute of Myology, Paris) et al., Poster Board Number 87P at Forum Hall, on Wednesday, October 9, 2024, 5:15 pm - 6:15 pm (CEST). Two communications at the European Society of Gene & Cell Therapy 31st Annual Congress, October 22-25, 2024 in La Nuvola, Rome, Italy, will describe Atamyo’s LGMD programs. Both posters will be presented during Poster Session II on Wednesday 23 October, 1:30 pm to 3 pm (CEST). • “Development of a quantitative alpha-dystroglycan glycosylation test in patients with Limb Girdle Muscular Dystrophy R9 treated in ATA-001-FKRP open-label multicenter AAV trial.”   E Thevenot (Genethon) et al., Poster number P0088 • “Natural history of limb girdle muscular dystrophy R9: two-year follow-up of a European cohort.”   S Olivier (Atamyo) et al., Poster number P0264 Two communications on Atamyo’s LGMD-R9 program will be presented at the ASGCT’s Breakthroughs in Muscular Dystrophy Conference, November 19-20, 2024, in Chicago, IL. • “Development of Gene Therapy for LGMD-R9.”   Oral presentation by E. Gicquel (Genethon), on November 19, 2024, 5:15 p.m. - 5:30 p.m. (US CDT), Great Lakes East Ballroom at the Westin Michigan Avenue Hotel. • “Overcoming Phenotypic Variability in Dystrophic Models: A Machine Learning Method for Refined Gene Therapy Evaluation.”   E. Brureau (Genethon) et al. Poster P27. Session on November 16, 2024, 8 a.m. - 7 p.m. (US CDT), Great Lakes East Ballroom at the Westin Michigan Avenue Hotel Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety. • “An engineered AAV targeting integrin alphaV beta 6 presents improved myotropism across species,” by Ai Vu Hong (Genethon), et al., was published in Nature Communications (https://doi.org/10.1038/s41467-024-52002-4). The paper describes development of the next-generation LICA-1 capsid by Isabelle Richard, Ph.D., Atamyo’s Chief Scientific Officer, and her Progressive Muscular Dystrophies Team at Genethon. Atamyo has rights to the LICA-1 capsid for cardiomyopathies indications. About Atamyo Therapeutics Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. For more information visit www.atamyo.com Contacts European contact: contact@atamyo.com U.S. Contact: Charles Craig, Opus Biotech Communications Charles.s.craig@gmail.com, 404-245-0591

HANNOVER, Germany--(BUSINESS WIRE)--Netradyne, a global provider of artificial intelligence (AI) technology solutions for fleet and driver safety, today announced a strategic partnership with Roos Fleetservice GmbH, a leading provider of fleet management in Germany, to bring Netradyne’s flagship product, Driver•i, to Roos Fleetservice’s European clients. The collaboration marks a substantial advancement in road safety and fleet management in the EU region and a significant milestone in Netradyne’s ongoing expansion across the European Union (EU), bringing its cutting-edge safety technology to a broader range of fleet organisations. Netradyne already runs commercial operations across the U.S., Germany, the U.K., India, Australia, New Zealand and Canada, with several hundred thousand installations across fleets of all sizes. Driver•i leverages AI, ML and Edge Computing to analyse 100% of driving time and set new vehicle safety standards. To date, Driver•i has processed over 15 billion miles of driving data, making the AI precise and accurate up to 99% - significantly reducing false alerts and gaining driver’s confidence in the technology. Roos Fleetservice is part of the Roos Vehicle Logistics GmbH, an established name offering a full suite of fleet management products. The company provides holistic fleet management with on-site installation and maintenance and additional services. “We see immense potential in our partnership with Roos to elevate vehicle safety standards and optimise fleet management across Europe through innovative technology,” said Durgadutt Nedungadi, Sr. Vice-President for International Business at Netradyne. “Driver•i’s driver scoring system, GreenZone, based on positive reinforcement, provides a holistic view of fleets and drivers, encouraging safe driving practices and ultimately enhancing road safety across Europe.” Maximilian Lorbach, CEO of Roos Fleetservice, commented, “Teaming up with Netradyne to introduce Driver•i to our European clients underscores our commitment to providing state-of-the-art fleet solutions that drive efficiency and safety for organisations of all sizes. Together, we aim to set new standards in vehicle safety and fleet management throughout the EU.” Contacts Liberty Comms on behalf of Netradyne: netradyne@libertycomms.com / +44 207 751 4444

On the International Identity Day ‘ID Day’, Thales reaffirms its dedication to supporting global identity initiatives and driving technological advancements that foster inclusion, security, and trust. Around the world, more than 850 million individuals do not have a legal identity, preventing them from claiming their rights and accessing fundamental citizen services e.g. health, education, employment. Thales has been working for more than thirty years to make trustworthy identities a reality for everyone, employing cutting-edge and responsible technology for biometrics and digital ID solutions. MEUDON, France--(BUSINESS WIRE)--#ThalesIDWallet--On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal 16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global efforts to guarantee every individual has access to a secure and trusted identity. Thales, a leading provider of secure physical and biometrics identification, has been actively involved in projects that are in line with the UN's Sustainable Development Goal 16.9, including birth registration, by 2030. According to the 2023 estimates from the World Bank's Identification for Development (ID4D) Initiative, over 850 million people globally lack an official ID. Thanks to global mobilization, the overall situation has improved since 2020 when 1 billion individuals were missing a legal ID. ID Day highlights the significance of having a legal identity and the positive impact it has on individuals and communities worldwide. A legal identity grants access to essential services, fosters social inclusion, and facilitates participation in the global economy. That is why Thales, recognised as the number one digital identity player by Juniper Research (in its “2024 Juniper Research Competitor Leaderboard”) stands for a future in which everyone could benefit from and confirm their trusted identity, leaving no one behind. "ID Day serves as a crucial reminder that identity is a fundamental human right. In today's interconnected world, having a secure and trusted legal ID is essential for accessing services, exercising rights, and fostering economic development. At Thales, we are committed to driving innovation in biometric and digital identity solutions, ensuring that every individual can claim their rightful place in society. Our goal is to support with our solutions a world where identity is secure, inclusive, and universally recognized," said Youzec Kurp, VP Identity and Biometrics Solutions at Thales Group. A secure identity is more than just a document; it is a gateway to opportunities and a cornerstone of trust in the digital age. Thales responsible biometrics (cf TrUE Biometrics1) and digital ID solutions are designed to meet the highest security standards, protecting individuals' personal data while facilitating seamless access to services as well as mobility. 1 TrUE Biometrics stands for Transparent, Understandable and finally Ethical. For years, Thales has developed highly secure solutions and biometrics has proved its full capacity to offer both security and convenience. While the technology serves a wide range of new needs triggered by our societies' digital transformation, Thales also supports initiatives that raise awareness of the benefits and risks of adopting biometric identification technologies. Thales is a reliable and responsible partner since it provides transparent, understandable, and ethical biometrics. About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion. PLEASE VISIT Thales GroupDigital Identity & Security ThalesThales Digital Identity and Security Contacts PRESS CONTACT Thales, Media RelationsDigital Identity and SecurityVanessa Viala +33 (0)6 07 34 00 34 vanessa.viala@thalesgroup.com

In e.l.f. SKIN’s largest awareness initiative to date, actress and comedian Megan Stalter tries to lure unsuspecting skincare sinners OAKLAND, Calif.--(BUSINESS WIRE)--e.l.f. SKIN launches today its most ambitious brand campaign to date: "Divine Skintervention." e.l.f. SKIN is positioned as the ultimate salvation for common skincare transgressions, offering a path to redemption for all skin types. In a vibrant, comedic exploration of skincare temptations, the campaign delves into the everyday skincare slip-ups —from pimple picking to the oh-so-relatable habit of sleeping in makeup. Actress and comedian Megan Stalter is the mischievous "Sinfluencer,” luring unsuspecting would-be skincare sinners into dreaded dilemmas. Here's the twist: e.l.f. SKIN is here to banish the shame, offering skincare salvation for skin sins with e.l.f.’s Holy Hydration! products. e.l.f. SKIN delivers premium-quality skincare at accessible prices with its signature value proposition. The brand offers straightforward, uncomplicated skincare solutions and is committed to e.l.f. clean, cruelty-free and vegan formulas. “We’ve all committed skincare sins – and there’s no e.l.f.ing shame in that! We’re just here to rescue the community from making more of them,” said Kory Marchisotto, e.l.f. Beauty’s Chief Marketing Officer. “With this campaign, we're putting a halo around proper skincare, demystifying horror stories that taking care of your skin is complex or cumbersome. We’ve made it e.l.f. SKIN’s priority to provide a straightforward routine that delivers great results without asking our community to have a PHD to understand it, or beaucoup bucks to access it.” According to a Statista study, Gen Z uses more skincare than any other generation*, but e.l.f. surveys prove Gen Z is also guilty of committing skin sins.** Fueled by community insights, e.l.f. SKIN has transformed real-life skincare confessions into a full-blown 360-degree “Divine Skintervention” initiative, rolling out across social media, television, and out-of-home platforms. The campaign also features an interactive landing page with a specialized quiz in the U.S. and the U.K. where consumers can "confess" their skincare sins and receive personalized product recommendations. The campaign and its creative were conceived and produced with e.l.f. creative partner Day One Agency, further boosting e.l.f.’s position as an entertainment brand that surprises and delights its community. e.l.f. SKIN has outpaced skincare category growth by 32x***, achieving top 10 brand status**** and quickly cementing its place as an accessible brand for every eye, lip, face and skin type. Aiming to continue growing its community, e.l.f. SKIN has focused its product innovation to launch holy grail product families in addition to Holy Hydration! and its recent viral success, Bronzing Drops. The spot will air on major streaming platforms such as Disney+, Peacock, Amazon Prime, Hulu, Netflix and Paramount+. Watch it on YouTube here: https://youtu.be/ctlPspAZdIE. *Statista Shoppers spending most on skin care in the beauty sector in the US 2021, by age group. **e.l.f. Cosmetics "e.l.f. BFFs” social group survey 2024. *** e.l.f. SKIN claim based on data reported by NielsenIQ through its Scantrack Service for the Mass Market Facial Skincare category for the 12-week period ending June 15, 2024 for the US xAOC channel according to e.l.f. SKIN custom product hierarchy. Copyright © 2024, Nielsen Consumer, LLC. ****Piper Sandler Taking Stock With Teens® survey spring 2024. About e.l.f. SKIN e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. e.l.f. SKIN champions e.l.f. clean and kind skincare by making innovative, efficacious formulas at accessible prices with universal appeal. e.l.f. SKIN is e.l.f. clean, vegan, double certified cruelty free Certified by both Leaping Bunny and PETA and Fair Trade certified. Learn more at www.elfcosmetics.com/elf-skin. Contacts e.l.f. Beauty Media Inquiries: Jennifer Budres jbudres@elfbeauty.com